Welcome to our dedicated page for Immunic SEC filings (Ticker: IMUX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Immunic, Inc. (IMUX) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission. As a Nasdaq-listed biotechnology issuer, Immunic uses filings such as Forms 10-K, 10-Q, and 8-K to report on its financial condition, clinical development progress, capital structure, and material corporate events.
Current reports on Form 8-K are particularly relevant for tracking Immunic’s milestones. Recent 8-K filings reference press releases on quarterly financial results and corporate updates, including spending on research and development for vidofludimus calcium (IMU-838) and other programs, as well as financings such as registered direct offerings and underwritten public offerings. Other 8-Ks describe presentation of new multiple sclerosis data at major scientific meetings and provide details on items like stock appreciation rights grants and Nasdaq listing notices regarding minimum bid price requirements.
Investors can also use SEC filings to monitor liquidity and risk disclosures, where Immunic discusses its cash and cash equivalents, the need to raise additional capital to fund operations, and the implications of financing structures. Filings may further elaborate on the company’s intellectual property strategy for vidofludimus calcium and other pipeline assets, complementing information in press releases.
On Stock Titan, these documents are supplemented with AI-powered summaries that explain key points in accessible language, helping readers quickly understand the significance of lengthy filings. Real-time updates from EDGAR ensure that new IMUX filings, including 10-Q and 10-K reports and any Form 4 insider transaction disclosures when available, are added promptly so users can review changes in ownership, compensation-related grants, and other governance matters alongside Immunic’s clinical and financial reporting.
Immunic, Inc. reported a 2025 net loss of $97.2M, slightly improved from $100.5M in 2024, as operating expenses rose modestly to $103.2M driven mainly by research and development spending of $82.0M.
The company highlighted an oversubscribed private placement of up to $400M in gross proceeds, including $200M already raised, which it expects to fund completion of phase 3 ENSURE trials in relapsing multiple sclerosis, initiate a phase 3 program in primary progressive multiple sclerosis and begin building a commercial organization. Management expects ENSURE top-line data by the end of 2026, a planned RMS NDA submission in the United States in mid-2027, and is targeting a potential regulatory approval date in 2028.
IMMUNIC, Inc. reports that Commodore Capital entities and two managing partners may be deemed to beneficially own 13,350,121 shares of Common Stock as of 02/17/2026.
The holding consists of 11,454,000 shares issuable on exercise of a Pre-Funded Warrant and 1,896,121 shares issuable on exercise of accompanying Common Warrants. A Beneficial Ownership Limitation of 9.99% applies. The filing references 120,284,724 shares outstanding as of 11/11/2025 reported in the issuer's Form 10-Q.
Immunic, Inc. reports a Schedule 13G filing showing 11,454,000 shares beneficially owned by Trails Edge entities and Ortav Yehudai. The filing states this equals 8.7% of the class as of the Event Date February 17, 2026.
Ownership consists of 5,727,000 shares underlying pre-funded warrants and 5,727,000 shares underlying warrants held directly by Trails Edge Biotechnology. The filing cites 120,284,724 shares outstanding as of November 11, 2025 for the percentage calculation.
Immunic, Inc. (IMUX) now has BVF and affiliated funds reporting beneficial ownership of 13,630,601 shares, or about 9.99% of the common stock. The position combines common shares and currently exercisable 2026 pre-funded warrants, subject to 9.99% ownership blockers that limit further warrant exercises.
BVF, BVF2, a Cayman trading fund and a managed account collectively hold large blocks of 2024, 2025 and 2026 pre-funded warrants plus matching Common Warrants, in total covering 53,257,500 shares each of 2026 pre-funded and Common Warrants. On February 12, 2026, they joined a private placement buying 2026 pre-funded warrants and Common Warrants at $0.873120 per unit.
The investors also participated in a Royalty Purchase Agreement under which 51,087,000 Series B warrants were exchanged for a pro rata share of a 5% synthetic royalty on future sales of Immunic’s vidofludimus calcium program. A reverse stock split of at least 10:1 will be put to stockholders, and BVF principal R. Thorvald Nagel has joined Immunic’s board as a Class III director.
Immunic, Inc. is asking shareholders to approve an amendment to effect a reverse stock split of its common stock at a ratio between 1-for-10 and 1-for-30, with the Board to select the final ratio within that range.
The Special Meeting is virtual, record date is February 20, 2026, and the proxy statement shows 130,464,825 shares outstanding as of February 19, 2026. The Board recommends a vote FOR Proposal 1; approval requires a majority of votes cast.
Immunic, Inc. ownership disclosure: Vivo Opportunity entities report beneficial ownership of convertible securities representing up to 29,126,906 shares (Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity, LLC) and 2,942,094 shares (Vivo Opportunity Cayman entities), each reported as 9.99% based on February 19, 2026.
The totals reflect an aggregate of pre-funded warrants and warrants exercisable into common stock within 60 days, but those instruments contain provisions preventing exercises that would exceed 9.99% ownership.
Immunic, Inc. ownership disclosure: Soleus Capital Master Fund, L.P. and related Soleus entities and Guy Levy report beneficial ownership of 6,792,000 shares of Common Stock, representing 5.5% of the class based on 120,284,724 shares outstanding as of November 11, 2025. The filing states these shares are held directly by Soleus Capital Master Fund, L.P.; related Soleus entities and Guy Levy disclaim beneficial ownership of the shares except for purposes of Section 13(d) obligations. The reported total includes 1,146,000 shares issuable upon exercise of pre-funded warrants and 1,146,000 shares issuable upon exercise of warrants exercisable following the issuer's contemplated reverse split.
Alyeska Investment Group and affiliates reported a 6.24% beneficial ownership stake in Immunic, Inc. common stock on a Schedule 13G/A. They report beneficial ownership of 7,500,000 shares, all through derivative securities rather than currently outstanding stock.
The reporting persons hold pre-funded warrants to purchase 3,750,000 shares of Immunic common stock and additional warrants to purchase 3,750,000 shares. The 6.24% figure is based on 120,284,724 Immunic shares outstanding, as disclosed in Immunic’s Form 10-Q filed on November 13, 2025.
Alyeska Investment Group, L.P., Alyeska Fund GP, LLC and individual reporting person Anand Parekh share voting and dispositive power over these 7,500,000 warrant-based shares and report no sole voting or dispositive power. They certify the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Immunic.
Immunic, Inc. received an updated ownership report from 683 Capital entities and Ari Zweiman. As of December 31, 2025, they may be deemed to beneficially own warrants exercisable for 7,500,000 shares of Immunic common stock. Based on shares outstanding plus these warrant shares, this represents about 5.9% of the company’s common stock. The filing states that the securities are not held for the purpose of changing or influencing control of Immunic.
Immunic, Inc. received an updated ownership disclosure from Nantahala Capital Management and its principals, Wilmot B. Harkey and Daniel Mack. As of December 31, 2025, they may be deemed to beneficially own 10,378,406 shares of Immunic common stock, representing 8.22% of the outstanding shares.
This stake includes 6,000,000 shares that can be acquired within sixty days through the exercise of warrants. The reporting persons have shared, but no sole, voting and dispositive power over these shares. They certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Immunic.